首页 | 本学科首页   官方微博 | 高级检索  
检索        

参松养心胶囊治疗阵发性心房颤动的多中心临床研究
作者姓名:Wang AH  Pu JL  Qi XY  Miao WL  Hou ZS  Cong HL  Zhou JZ  Liu XF  Li SM  Han QH  Liu YJ  Yang XC
作者单位:1. 首都医科大学附属北京朝阳医院心脏中心,北京,100020
2. 中国医学科学院阜外心血管病医院
3. 河北省人民医院心内科
4. 沈阳医学院沈洲心血管病医院
5. 山东省临沂市人民医院
6. 天津胸科医院
7. 重庆医科大学附属第一医院
8. 宁夏医科大学附属医院
9. 吉林医科大学第二附属医院
10. 山西医科大学第一医院
11. 成都中医药大学附属医院
基金项目:国家重点基础研究发展计划"973"项目
摘    要:目的 评价复方中药参松养心胶囊治疗阵发性心房颤动(房颤)的有效性及安全性.方法 自2007年8月至2008年7月,采用随机、双盲、双模拟、平行对照、多中心临床试验方法,在11家临床医院的门诊患者,选择年龄18~75岁,男女不限,阵发性房颤发作频率≥2次/月的受试者,按1:1:1比例随机数字分组分为3组:(1)参松养心组:服用参松养心胶囊4粒+普罗帕酮模拟剂150 mg,1日3次;(2)普罗帕组:服用普罗帕酮片150 mg+参松养心胶囊模拟剂4粒,1日3次;(3)参松养心+普罗帕酮组:服用参松养心胶囊4粒+普罗帕酮片150 mg,1日3次.门诊随访1次/月,疗程为8周.结果 共纳入阵发性房颤患者349例,其中参松养心组和参松养心+普罗帕酮组各117例,普罗帕酮组115例;3组患者的基线房颤发作频率、24 h动态心电图、心脏超声及症状等指标差异均无统计学意义(均P>0.05).经8周治疗,房颤发作频率(由平均6 次/月降至2 次/月,P<0.01)、房颤发作例数参松养心组从46(43.8%)降至22(20.8%)例,普罗帕酮组从43(43.4%)例降至25(25.3%)例,参松养心+普罗帕酮组从40(40.6%)降至31(29.2%)例,P<0.01]、房颤发作持续时间(参松养心组,普罗帕酮组从4 h 降至0.5 h,参松养心+普罗帕酮组从4.25 h降至0.5 h,P<0.01)均显著下降,房颤总体疗效参松养心组62.3%,普罗帕酮组58.6%,参松养心+普罗帕酮组58.5%.参松养心组发生不良反应2例(1.8%),普罗帕酮组和参松养心+普罗帕酮组分别发生不良反应9例(8.2%)和6例(5.4%).结论 参松养心胶囊与普罗帕酮治疗阵发性房颤疗效相当;参松养心胶囊具有良好的安全性.
Abstract:
Objective To evaluate the efficacy and safety of Chinese medicinal shensongyangxin capsules in the treatment of paroxysmal atrial fibrillation. Methods From August 2007 to July 2008, Beijing Chaoyang Hospital coducted a multicenter study, select the eleven hospital's outpatient subjects, aged 18 to 75 years old, male or female, paroxysmal atrial fibrillation (at least one electrocardiogram diagnosis) seizure frequency ≥ 2 times / month, groups: a. Shensongyangxin group, taking shensongyangxin capsule 4 + propafenone analogues 150 mg, 3 times a day; b. Propafenone group, taking propafenone tablets 150 mg + 4 shensongyangxin analogues, 3 times a day; shensongyangxin capsule + propafenone group, taking shensongyangxin capsule 4 + propafenone 150 mg, 3 times a day. The treatment course is 8 weeks, with 3 times of follow-up.Results Total of 349 cases of paroxysmal atrial fibrillation, which 117 cases in shensongyangxin group, 115 cases in propafenone group; 117cases in shensongyangxin + propafenone group.The baseline data analysis showed that there were no significantly difference (P>0.05) among the three groups of atrial fibrillation seizure frequency, vital signs, general condition, medical history, 24-hour ambulatory ECG, 12-lead normal electrocardiogram, cardiac ultrasound and symptoms. The comparioson before and after (8 weeks ) treatment showed that the frequency(from 6 times/m to 2 times/m in each group, P<0.01), number of cases from 46(43.3%) to 22(20.8%), 43(43.4%) to 25(25.3%), and 40(40.6%) to 31(29.2%), respectively P<0.01] and dutaion time of attack of atrial fibrillation (from 4 h to 0.5 h,4 h to 0.5 h, and 4.25 h to 0.5 h, respectively P<0.01) all decreased in three groups.No significant difference among the three groups comparing the overall effect (62.3%,58.6%, and 58.5%, respectively, P>0.05), while the efficiacy of TCM symptoms in shensongyangxin group(80.2%) was better than that of propafenone group(67.7%)( P<0.05). Safety evaluation showed that adverse reaction rate was 1.8% in shensongyangxin group, and 8.2% and 5.4% in propafenone group and shensongyangxin + propafenone group.Conclusion Shensongyangxin capsules and propafenone have comparable efficacies in the treatment of PAF. The efficacy of TCM symptoms is better than propafenone. Shensongyangxin capsules have an excellent profile of safety.

关 键 词:心房颤动  参松养心胶囊  普罗帕酮

Evaluation of shensongyangxin capsules in the treatment of paroxysmal atrial fibrillation: a randomized, double-blind and controlled multicenter trial
Wang AH,Pu JL,Qi XY,Miao WL,Hou ZS,Cong HL,Zhou JZ,Liu XF,Li SM,Han QH,Liu YJ,Yang XC.Evaluation of shensongyangxin capsules in the treatment of paroxysmal atrial fibrillation: a randomized, double-blind and controlled multicenter trial[J].National Medical Journal of China,2011,91(24):1677-1681.
Authors:Wang Ai-hu  Pu Jie-lin  Qi Xiao-yong  Miao Wen-lin  Hou Zi-shan  Cong Hong-liang  Zhou Jian-zhong  Liu Xiao-fang  Li Shu-mei  Han Qing-hua  Liu Yong-Jia  Yang Xin-chun
Institution:Department of Cardiology, Capital Medical University, Beijing 100020, China.
Abstract:Objective To evaluate the efficacy and safety of Chinese medicinal shensongyangxin capsules in the treatment of paroxysmal atrial fibrillation. Methods From August 2007 to July 2008, Beijing Chaoyang Hospital coducted a multicenter study, select the eleven hospital's outpatient subjects, aged 18 to 75 years old, male or female, paroxysmal atrial fibrillation (at least one electrocardiogram diagnosis) seizure frequency ≥ 2 times / month, groups: a. Shensongyangxin group, taking shensongyangxin capsule 4 + propafenone analogues 150 mg, 3 times a day; b. Propafenone group, taking propafenone tablets 150 mg + 4 shensongyangxin analogues, 3 times a day; shensongyangxin capsule + propafenone group, taking shensongyangxin capsule 4 + propafenone 150 mg, 3 times a day. The treatment course is 8 weeks, with 3 times of follow-up.Results Total of 349 cases of paroxysmal atrial fibrillation, which 117 cases in shensongyangxin group, 115 cases in propafenone group; 117cases in shensongyangxin + propafenone group.The baseline data analysis showed that there were no significantly difference (P>0.05) among the three groups of atrial fibrillation seizure frequency, vital signs, general condition, medical history, 24-hour ambulatory ECG, 12-lead normal electrocardiogram, cardiac ultrasound and symptoms. The comparioson before and after (8 weeks ) treatment showed that the frequency(from 6 times/m to 2 times/m in each group, P<0.01), number of cases from 46(43.3%) to 22(20.8%), 43(43.4%) to 25(25.3%), and 40(40.6%) to 31(29.2%), respectively P<0.01] and dutaion time of attack of atrial fibrillation (from 4 h to 0.5 h,4 h to 0.5 h, and 4.25 h to 0.5 h, respectively P<0.01) all decreased in three groups.No significant difference among the three groups comparing the overall effect (62.3%,58.6%, and 58.5%, respectively, P>0.05), while the efficiacy of TCM symptoms in shensongyangxin group(80.2%) was better than that of propafenone group(67.7%)( P<0.05). Safety evaluation showed that adverse reaction rate was 1.8% in shensongyangxin group, and 8.2% and 5.4% in propafenone group and shensongyangxin + propafenone group.Conclusion Shensongyangxin capsules and propafenone have comparable efficacies in the treatment of PAF. The efficacy of TCM symptoms is better than propafenone. Shensongyangxin capsules have an excellent profile of safety.
Keywords:Atrial fibrillation  Shensongyangxin capsules  Propafenone
本文献已被 万方数据 PubMed 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号